BamSEC and AlphaSense Join Forces
Learn More

Endonovo Therapeutics Inc

OTC: ENDV    
Share price (11/22/24): $0.00    
Market cap (11/22/24): $278 thousand
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 4 pages Amendment to Agreement
12/34/56
EX-10.1
from 8-K 38 pages Asset Purchase Agreement
12/34/56
EX-10.1
from 8-K 11 pages March 23, 2023 Alan Collier, CEO Endonovo Therapeutics, Inc. 6320 Canoga Avenue, 15th Floor Woodland Hills, Ca 91367 Subject: Purchase of Sofpulse, Inc. 1. Structure of Transaction
12/34/56
EX-10.1
from 8-K 36 pages Asset Purchase Agreement
12/34/56
EX-10.3
from 8-K 3 pages Note Modification and Forebareance Agreement
12/34/56
EX-10.2
from 8-K 12 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 44 pages Equity Line Purchase Agreement
12/34/56
EX-10.2
from 8-K 13 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 32 pages Investment Agreement
12/34/56
EX-10.2
from 8-K 9 pages Endonovo Therapeutics, Inc. 10% Senior Secured Convertible Redeemable Note Due November 30, 2019
12/34/56
EX-10.1
from 8-K 18 pages Exchange Agreement
12/34/56
EX-10.1
from 8-K 17 pages Sales and Marketing Agreement
12/34/56
EX-10.8
from 10-K 9 pages Material contract
12/34/56
EX-10.7
from 10-K 10 pages Material contract
12/34/56
EX-10.6
from 10-K 10 pages Material contract
12/34/56
EX-10.3
from 10-K 56 pages Material contract
12/34/56
EX-10.4
from 8-K 11 pages Except as Permitted by Section 8 Hereof, No Transfer Shall Be Made at Any Time Unless the Company Shall Have Been Supplied With Evidence Reasonably Satisfactory to It That Such Transfer Is Not in Violation of the Securities Act of 1933, as Amended (The “Act”)
12/34/56
EX-10.3
from 8-K 9 pages Security Agreement
12/34/56
EX-10.2
from 8-K 9 pages Endonovo Therapeutics, Inc. 10% Convertible Secured Redeemable Note Due December 21, 2018
12/34/56
EX-10.1
from 8-K 15 pages Securities Purchase Agreement
12/34/56